Tomvi

Tenvie is a clinical-stage biotechnology company dedicated to transforming the treatment of neurological and peripheral diseases by addressing core drivers such as neuroinflammation and cellular dysfunction. The company utilizes a validated, CNS-centric small molecule product engine to develop precision-engineered therapies capable of deep brain penetration or peripheral restriction. Tenvie's lead programs include TNV108, an allosteric SARM1 inhibitor, and TNV262, a fully CNS-penetrant NLRP3 inhibitor, both of which have entered Phase 1 clinical trials. By targeting the root causes of disease, Tenvie aims to improve the lives of patients and caregivers impacted by complex conditions like neurodegeneration and metabolic disorders.